CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer

被引：0
|
作者：
Sam Z. Thalji
Mandana Kamgar
Ben George
Mohammed Aldakkak
Kathleen K. Christians
Callisia N. Clarke
Beth A. Erickson
William A. Hall
Parag P. Tolat
Zachary L. Smith
Douglas B. Evans
Susan Tsai
机构：
[1] Medical College of Wisconsin,Department of Surgery, Division of Surgical Oncology, LaBahn Pancreatic Cancer Program
[2] Medical College of Wisconsin,Department of Medicine, Division of Medical Oncology, LaBahn Pancreatic Cancer Program
[3] Medical College of Wisconsin,Department of Radiation Oncology, LaBahn Pancreatic Cancer Program
[4] Medical College of Wisconsin,Department of Radiology, LaBahn Pancreatic Cancer Program
[5] Medical College of Wisconsin,Department of Medicine, Division of Gastroenterology and Hepatology, LaBahn Pancreatic Cancer Program
来源：
Annals of Surgical Oncology | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3013 / 3021
页数：8
相关论文
共 50 条
  • [41] Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine plus nab-paclitaxel
    Vivaldi, C.
    Cappelli, C.
    Donati, F.
    Fornaro, L.
    Musettini, G.
    Pasquini, G.
    Pecora, I.
    Catanese, S.
    Lencioni, M.
    Salani, F.
    Boraschi, P.
    Falcone, A.
    Vasile, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis
    Hayuka, Kotone
    Okuyama, Hiroyuki
    Murakami, Akitsu
    Okita, Yoshihiro
    Nishiuchi, Takamasa
    Okano, Keiichi
    Suzuki, Yasuyuki
    Tsuji, Akihito
    CHEMOTHERAPY, 2021, 66 (03) : 58 - 64
  • [43] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [44] Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence
    Caponnetto, S.
    Gelibter, A.
    Mosillo, C.
    Magri, V.
    Scagnoli, S.
    Pomati, G.
    Piesco, G.
    Verkhovskaya, S.
    Pisegna, S.
    Sirgiovanni, G.
    Napoli, V.
    Buscicchio, D.
    Iannantuono, G. M.
    Marinelli, D.
    Mammone, G.
    Pannunzio, S.
    Nicolo, E.
    Stefani, A.
    Astorino, V.
    Mancini, M.
    Cortesi, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE CHEMOTHERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA AFTER GEMCITABINE PLUS NAB-PACLITAXEL FAILURE
    Ikezawa, Kenji
    Kiyota, Ryosuke
    Takada, Ryoji
    Imai, Toshihiro
    Yutaro, Abe
    Fukutake, Nobuyasu
    Takatoshi, Nawa
    Katayama, Kazuhiro
    Ohkawa, Kazuyoshi
    GASTROENTEROLOGY, 2020, 158 (06) : S527 - S527
  • [46] First-line Nab-paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer from Routine Clinical Practice
    Vogel, Arndt
    Pelzer, Uwe
    Salah-Eddin, Al-Batran
    Koester, Wolf
    IN VIVO, 2014, 28 (06): : 1135 - 1140
  • [47] Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients
    Pecora, I.
    Vivaldi, C.
    Rovesti, G.
    Catanese, S.
    Salani, F.
    Gardini, A. Casadei
    Massa, V.
    Bernardini, L.
    Riggi, M.
    Andrikou, K.
    Rapposelli, I.
    Formica, V.
    Cesario, S.
    Caccese, M.
    Lencioni, M.
    Vasile, E.
    Falcone, A.
    Fornaro, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S151 - S151
  • [48] Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
    Riedl, J. M.
    Posch, F.
    Horvath, L.
    Gantschnigg, A.
    Renneberg, F.
    Schwarzenbacher, E.
    Moik, F.
    Barth, D.
    Stotz, M.
    Schaberl-Moser, R.
    Pichler, M.
    Stoeger, H.
    Greil, R.
    Djanani, A.
    Schlick, K.
    Gerger, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S942 - S942
  • [49] Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine plus nab-paclitaxel or gemcitabine-monotherapy in routine clinical practice across Europe
    Prager, G.
    Macarulla Mercade, T.
    Mellbring, A.
    Taieb, J.
    Carrato, A.
    Melisi, D.
    Westphalen, B.
    D'Esquermes, N.
    Ferreras, A.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 93 - 93
  • [50] Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
    Mie, Takafumi
    Sasaki, Takashi
    Takeda, Tsuyoshi
    Okamoto, Takeshi
    Hamada, Tsuyoshi
    Ishitsuka, Takahiro
    Yamada, Manabu
    Nakagawa, Hiroki
    Furukawa, Takaaki
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    CANCERS, 2023, 15 (02)
12345